Amgen Inc. $AMGN Shares Bought by First Financial Bankshares Inc

First Financial Bankshares Inc grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 220,422 shares of the medical research company’s stock after purchasing an additional 1,552 shares during the period. First Financial Bankshares Inc’s holdings in Amgen were worth $62,203,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of AMGN. Legacy Investment Solutions LLC acquired a new position in Amgen in the second quarter valued at about $27,000. Evelyn Partners Investment Management LLP purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen in the 2nd quarter worth approximately $32,000. Quaker Wealth Management LLC boosted its position in shares of Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after purchasing an additional 240 shares during the period. Finally, Cloud Capital Management LLC purchased a new position in shares of Amgen during the 3rd quarter worth approximately $34,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AMGN. UBS Group upped their price target on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. The Goldman Sachs Group increased their target price on Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Wells Fargo & Company raised their target price on Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a report on Thursday. Morgan Stanley boosted their price target on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Finally, Daiwa Securities Group increased their price target on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $351.76.

Amgen Stock Performance

Shares of Amgen stock opened at $379.42 on Tuesday. The business has a 50-day simple moving average of $344.29 and a 200-day simple moving average of $317.21. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a one year low of $261.43 and a one year high of $385.12. The company has a market cap of $204.53 billion, a PE ratio of 26.66, a P/E/G ratio of 3.71 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the firm earned $5.31 earnings per share. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.